In the latest trading session, Abbott (ABT) closed at $119.02, marking a +0.98% move from the previous day. The stock's change was less than the S&P 500's daily gain of 2.11%. Elsewhere, the Dow saw an upswing of 1.18%, while the tech-heavy Nasdaq appreciated by 2.96%.The the stock of maker of infant formula, medical devices and drugs has risen by 6.41% in the past month, leading the Medical sector's gain of 3.98% and the S&P 500's gain of 3.08%.The upcoming earnings release of Abbott will be of great inter ...

Abbott Laboratories reported strong earnings Wednesday, despite spending recent months responding to ... [+] criticism over problems that led to the shutdown of one of its infant formula-producing plants. (Stacey Wescott/Chicago Tribune/Tribune News Service via Getty Images)TNSAbbott (NYSE: ABT) reported its Q4 results last month, with revenues above and earnings aligning with the street estimates. The company reported revenue of $10.24 billion and earnings of $1.19 on a per-share and adjusted basis, compar ...

Humana HUM announced today that its Board of Directors has declared a cash dividend to stockholders of $0.885 per share payable on April 26, 2024 to stockholders of record as of the close of business on March 29, 2024.The Board of Directors of FedEx today declared a quarterly cash dividend of $1.26 per share on FedEx common stock, in line with the company's continued focus on delivering stockholder value. The dividend is payable April 1, 2024 to stockholders of record at the close of business on March 11, 2 ...

ABBOTT PARK, Ill., Feb. 16, 2024 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 55 cents per share. This marks the 401st consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable May 15, 2024, to shareholders of record at the close of business on April 15, 2024. Abbott has increased its dividend payout for 52 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that h ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 ______________________________________________ FORM 10-K (MARK ONE) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 _______________________________________________________ For the fiscal year ended December 31, 2023 Commission file number 1-2189 Abbott Laboratories An Illinois Corporatio ...

Abbott Laboratories ABT, -1.06% said that a Food and Drug Administration panel voted in favor of the safety profile of its heart device TriClip. The medical device company on Tuesday said that the Circulatory System Devices Panel of the Medical Devices Advisory Committee also confirmed the effectiveness and risk/benefit profile of the device to treat people with tricuspid regurgitation. Tricuspid regurgitation is a type of heart valve disease that occurs when the tricuspid valve doesn’t close tight enoug ...

Panel of independent experts reviewed data from the TRILUMINATE™ pivotal trial demonstrating safety, effectiveness and quality-of-life benefits of the TriClip system An investigational device in the U.S., TriClip is approved in more than 50 countries and has treated more than 10,000 people with tricuspid regurgitation worldwide ABBOTT PARK, Ill., Feb. 13, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the Circulatory System Devices Panel of the Medical Devices Advisory Committee for the U.S. ...

One of the biggest themes in the healthcare industry right now is the rise of effective new obesity and diabetes medications. Novo Nordisk and Eli Lilly are dominating the space with blockbuster drugs including Ozempic, Rybelsus, Wegovy, Mounjaro, and Zepbound.As demand for these glucagon-like peptide-1 (GLP-1) agonists continues to surge, other pharmaceutical companies, including Hims & Hers Health and start-up Ro, are looking to make inroads with their own versions.But savvy investors understand that othe ...

The health sector has two things to offer: new ideas and consistent returns. As a result, healthcare stocks will continue to be a good choice for investors looking for growth opportunities in 2024. The sector is valuable because it has stayed flexible and grown along with improvements in medical tools, treatment methods, and healthcare services all around the world.This rapid rise sparked companies in the sector. It was also expected to raise living standards by offering new medical solutions. So, when we b ...

Abbott (ABT) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Over the past month, shares of this maker of infant formula, medical devices and drugs have returned -0.9%, compared to the Zacks S&P 500 composite's +5.1% change. During this period, the Zacks Medical - Products industry, which Abbott falls in, has gained 2.6%. The key question now is: What could be the ...